| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.66▼ | 1.61▲ | 1.62▲ | 1.61▲ | 1.53▲ |
| MA10 | 1.66▼ | 1.61▲ | 1.62▲ | 1.59▲ | 1.55▲ |
| MA20 | 1.63▲ | 1.62▲ | 1.62▲ | 1.50▲ | 2.07▼ |
| MA50 | 1.63▲ | 1.60▲ | 1.59▲ | 1.52▲ | 2.07▼ |
| MA100 | 1.61▲ | 1.58▲ | 1.52▲ | 2.05▼ | 3.91▼ |
| MA200 | 1.59▲ | 1.47▲ | 1.45▲ | 1.97▼ | 8.91▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.004▲ | 0.002▲ | 0.001▲ | 0.026▲ | -0.016▼ |
| RSI | 54.739▲ | 56.449▲ | 55.481▲ | 59.066▲ | 45.193▼ |
| STOCH | 76.699 | 45.370 | 39.583 | 74.078 | 38.846 |
| WILL %R | -29.167 | -29.167 | -29.167 | -13.043▲ | -71.123 |
| CCI | 28.864 | 133.522▲ | 129.842▲ | 105.362▲ | -18.318 |
|
Wednesday, December 10, 2025 10:05 PM
Featured In Networknewsaudio APR On Urgent Need For Rare Disease Therapies. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, is highlighted in ...
|
|
Tuesday, December 02, 2025 06:16 AM
Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially ...
|
|
Thursday, November 20, 2025 10:24 AM
Enrollment in FLASH2 Trial Reaches 50; Interim Analysis in 2Q26 On November 19, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced that enrollment in the FLASH2 trial of HyBryte™ for the treatment of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 12/12/25 | 1.63 | 1.695 | 1.5611 | 1.65 | 348,989 |
| 11/12/25 | 1.60 | 1.67 | 1.60 | 1.63 | 362,671 |
| 10/12/25 | 1.62 | 1.65 | 1.545 | 1.60 | 369,505 |
| 09/12/25 | 1.56 | 1.63 | 1.56 | 1.59 | 110,000 |
| 08/12/25 | 1.62 | 1.62 | 1.51 | 1.58 | 404,700 |
| 05/12/25 | 1.64 | 1.67 | 1.495 | 1.61 | 775,022 |
| 04/12/25 | 1.54 | 1.67 | 1.51 | 1.63 | 239,800 |
| 03/12/25 | 1.57 | 1.58 | 1.50 | 1.55 | 202,000 |
| 02/12/25 | 1.53 | 1.60 | 1.48 | 1.58 | 203,900 |
| 01/12/25 | 1.57 | 1.59 | 1.48 | 1.52 | 263,300 |
|
|
||||
|
|
||||
|
|